Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2025 08:00 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

Maintains Brain Connectivity: GAL-201 prevents amyloid-beta (Aβ)–induced synaptic damage by maintaining long-term potentiation, a correlate for learning and memory.Improves Memory and Behavior:...